Previous 10 | Next 10 |
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2021 finan...
CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 2021 fina...
Section 32 Raises $740 Million Venture Fund --Firm's Fourth Fund Maintains its Strategy of Investing in Companies at the Intersection of Technology and Healthcare; Firm Adds Nina Labatt as Chief Operating Officer and Chief Financial Officer-- PR Newswire SAN DIEGO ...
Shares of Relay Therapeutics (NASDAQ: RLAY) , a clinical-stage biopharmaceutical company, have risen about 30% since the stock's closing price last Friday. Investors are highly encouraged by interim clinical trial data that suggest the company's new approach to drug development can ...
Gainers: Hyzon Motors HYZN +5%. Avadel Pharmaceuticals (NASDAQ:AVDL) +4%. Allogene Therapeutics (NASDAQ:ALLO) +4%. Latch (NASDAQ:LTCH) +2%. Old National Bancorp (NASDAQ:ONB) +2%. Losers: Xiaobai Maimai (NASDAQ:HX) -4%. Clarus Therapeutics Holdings (NASDAQ:CRXT) -4%. Relay Thera...
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwrit...
M&A headlines provided a key theme in Tuesday's pre-market trading. A host of private-equity firms are reportedly looking at GlaxoSmithKline's (NYSE:GSK) consumer unit. Meanwhile, Signet Jewelers (NYSE:SIG) rallied on a $490M purchase and raised guidance. In other news, Nike (NYSE:NKE) dr...
Gainers: QTRX +18.5%. PROG +3.7%. MTTR +2.6%. KC +2.5%. LFMD +2.2%. Losers: RLAY -8.9%. HX -6.2%. ACHL -3.4%. STLD -2.0%. ARRY -1.9%. For further details see: QTRX, PROG, RLAY and HX among after hours movers
CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced ...
Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4) RLY-4008 demonstrated tumor shrinkage in all six pan-FGFR treatment-naïve FGFR2 fusion positi...
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
Relay Therapeutics Inc. Website:
2024-06-14 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay T...
CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collabor...